Spinraza

Chemical Namenusinersen
Dosage FormInjection (intrathecal; 12 mg/5 mL)
Drug ClassOligonucleotides
SystemMusculoskeletal
CompanyBiogen Idec
Approval Year2016

Indication

  • To treat children and adults with spinal muscular atrophy (SMA).
Last updated on 10/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Spinraza (nusinersen) Prescribing Information 2019Biogen, Cambridge, MA